Loading...

We've got a brand new version of Simply Wall St! Try it out

MJardin Group

CNSX:MJAR
Snowflake Description

Fair value with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MJAR
CNSX
CA$49M
Market Cap
  1. Home
  2. CA
  3. Pharmaceuticals & Biotech
Company description

MJardin Group, Inc., through its subsidiaries, engages in the cultivation, processing, distribution, and retail of cannabis products in Canada. The last earnings update was 24 days ago. More info.


Add to Portfolio Compare Print
  • MJardin Group has significant price volatility in the past 3 months.
MJAR Share Price and Events
7 Day Returns
-27.3%
CNSX:MJAR
-5.9%
CA Pharmaceuticals
1.3%
CA Market
1 Year Returns
-
CNSX:MJAR
-46.7%
CA Pharmaceuticals
-0.1%
CA Market
MJAR Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MJardin Group (MJAR) -27.3% -35.7% -44.2% - - -
CA Pharmaceuticals -5.9% -3.4% -24.8% -46.7% 217.3% 286.4%
CA Market 1.3% 4.2% 1.6% -0.1% 8.4% 5.7%
1 Year Return vs Industry and Market
  • No trading data on MJAR.
  • No trading data on MJAR.
Price Volatility
Industry
5yr Volatility vs Market

Value

 Is MJardin Group undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of MJardin Group to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for MJardin Group.

CNSX:MJAR Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 1 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 13.7%
Perpetual Growth Rate 10-Year CA Government Bond Rate 1.9%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CNSX:MJAR
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year CA Govt Bond Rate 1.9%
Equity Risk Premium S&P Global 6%
Pharmaceuticals Unlevered Beta Simply Wall St/ S&P Global 0.7
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.698 (1 + (1- 21%) (315.55%))
1.964
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.96
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.95% + (1.964 * 5.96%)
13.65%

Discounted Cash Flow Calculation for CNSX:MJAR using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for MJardin Group is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

CNSX:MJAR DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (CAD, Millions) Source Present Value
Discounted (@ 13.65%)
2020 33.28 Analyst x1 29.28
2021 48.43 Est @ 45.52% 37.49
2022 64.14 Est @ 32.44% 43.69
2023 79.08 Est @ 23.3% 47.40
2024 92.44 Est @ 16.89% 48.75
2025 103.91 Est @ 12.41% 48.21
2026 113.54 Est @ 9.27% 46.35
2027 121.57 Est @ 7.07% 43.67
2028 128.30 Est @ 5.54% 40.55
2029 134.02 Est @ 4.46% 37.27
Present value of next 10 years cash flows CA$422.00
CNSX:MJAR DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= CA$134.02 × (1 + 1.95%) ÷ (13.65% – 1.95%)
CA$1,167.17
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= CA$1,167.17 ÷ (1 + 13.65%)10
CA$324.58
CNSX:MJAR Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= CA$422.00 + CA$324.58
CA$746.58
Equity Value per Share
(CAD)
= Total value / Shares Outstanding
= CA$746.58 / 67.46
CA$11.07
CNSX:MJAR Discount to Share Price
Calculation Result
Value per share (CAD) From above. CA$11.07
Current discount Discount to share price of CA$0.72
= -1 x (CA$0.72 - CA$11.07) / CA$11.07
93.5%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price MJardin Group is available for.
Intrinsic value
>50%
Share price is CA$0.72 vs Future cash flow value of CA$11.07
Current Discount Checks
For MJardin Group to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • MJardin Group's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • MJardin Group's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MJardin Group's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MJardin Group's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CNSX:MJAR PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in CAD CA$-1.70
CNSX:MJAR Share Price ** CNSX (2019-09-20) in CAD CA$0.72
Canada Pharmaceuticals Industry PE Ratio Median Figure of 13 Publicly-Listed Pharmaceuticals Companies 15.3x
Canada Market PE Ratio Median Figure of 539 Publicly-Listed Companies 14.14x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MJardin Group.

CNSX:MJAR PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CNSX:MJAR Share Price ÷ EPS (both in CAD)

= 0.72 ÷ -1.70

-0.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MJardin Group is loss making, we can't compare its value to the CA Pharmaceuticals industry average.
  • MJardin Group is loss making, we can't compare the value of its earnings to the Canada market.
Price based on expected Growth
Does MJardin Group's expected growth come at a high price?
Raw Data
CNSX:MJAR PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Canada Pharmaceuticals Industry PEG Ratio Median Figure of 7 Publicly-Listed Pharmaceuticals Companies 1.56x
Canada Market PEG Ratio Median Figure of 245 Publicly-Listed Companies 1.02x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MJardin Group, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MJardin Group's assets?
Raw Data
CNSX:MJAR PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in CAD CA$2.38
CNSX:MJAR Share Price * CNSX (2019-09-20) in CAD CA$0.72
Canada Pharmaceuticals Industry PB Ratio Median Figure of 151 Publicly-Listed Pharmaceuticals Companies 2.36x
Canada Market PB Ratio Median Figure of 2,457 Publicly-Listed Companies 1.43x
CNSX:MJAR PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CNSX:MJAR Share Price ÷ Book Value per Share (both in CAD)

= 0.72 ÷ 2.38

0.3x

* Primary Listing of MJardin Group.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MJardin Group is good value based on assets compared to the CA Pharmaceuticals industry average.
X
Value checks
We assess MJardin Group's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. MJardin Group has a total score of 3/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is MJardin Group expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
93.3%
Expected annual growth in revenue.
Earnings growth vs Low Risk Savings
Is MJardin Group expected to grow at an attractive rate?
  • Unable to compare MJardin Group's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MJardin Group's earnings growth to the Canada market average as no estimate data is available.
  • MJardin Group's revenue growth is expected to exceed the Canada market average.
Annual Growth Rates Comparison
Raw Data
CNSX:MJAR Future Growth Rates Data Sources
Data Point Source Value (per year)
CNSX:MJAR Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 93.3%
Canada Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 97.7%
Canada Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 56.5%
Canada Market Earnings Growth Rate Market Cap Weighted Average 12.6%
Canada Market Revenue Growth Rate Market Cap Weighted Average 5.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CNSX:MJAR Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CNSX:MJAR Future Estimates Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-12-31 119 1
2019-12-31 42 1
2019-09-22
CNSX:MJAR Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-06-30 33 -45 -99
2019-03-31 31 -36 -91
2018-12-31 28 -30 -84
2018-09-30 26 -6 -8
2018-06-30 22 -4 -6
2018-03-31 22 -4 -1
2017-12-31 20 2 2
2016-12-31 16 -1 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MJardin Group is high growth as no earnings estimate data is available.
  • MJardin Group's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CNSX:MJAR Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from MJardin Group Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MJAR Future Estimates Data
Date (Data in CAD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-12-31
2019-12-31
2019-09-22
CNSX:MJAR Past Financials Data
Date (Data in CAD Millions) EPS *
2019-06-30 -1.70
2019-03-31 -1.67
2018-12-31 -2.07
2018-09-30 -0.17
2018-06-30 -0.15
2018-03-31 -0.03
2017-12-31 0.08
2016-12-31 -0.09

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MJardin Group will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess MJardin Group's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Canada market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Canada market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MJardin Group has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has MJardin Group performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MJardin Group's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MJardin Group does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare MJardin Group's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MJardin Group's 1-year growth to the CA Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
MJardin Group's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MJardin Group Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CNSX:MJAR Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 32.55 -99.08 54.22
2019-03-31 31.49 -90.61 42.72
2018-12-31 27.51 -84.25 37.81
2018-09-30 25.56 -7.53 5.10
2018-06-30 22.46 -6.15 25.86
2018-03-31 21.78 -0.59 20.07
2017-12-31 19.94 1.52 18.29
2016-12-31 15.87 -1.21 2.32
2015-12-31 4.17 -3.08 2.11

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MJardin Group has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if MJardin Group has efficiently used its assets last year compared to the CA Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MJardin Group improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess MJardin Group's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MJardin Group has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is MJardin Group's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MJardin Group's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MJardin Group is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • MJardin Group's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of MJardin Group's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is not covered by short term assets, assets are 0.3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MJardin Group Company Filings, last reported 2 months ago.

CNSX:MJAR Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 179.41 149.70 15.74
2019-03-31 151.56 143.68 19.18
2018-12-31 161.75 140.57 30.44
2018-09-30 54.88 41.12 3.19
2018-06-30 39.26 26.79 1.82
2018-03-31 16.10 52.85 7.11
2017-12-31 16.10 52.85 7.11
2016-12-31 1.44 0.00 0.90
2015-12-31 2.74 0.00 1.70
  • MJardin Group's level of debt (83.4%) compared to net worth is high (greater than 40%).
  • Unable to establish if MJardin Group's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MJardin Group has less than a year of cash runway based on current free cash flow.
  • Unable to confirm if MJardin Group has at least 1 year of cash runway based on growing free cash flows without relevant data.
X
Financial health checks
We assess MJardin Group's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MJardin Group has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is MJardin Group's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MJardin Group dividends.
If you bought CA$2,000 of MJardin Group shares you are expected to receive CA$0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MJardin Group's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MJardin Group's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CNSX:MJAR Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
North America Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 2.8%
Canada Market Average Dividend Yield Market Cap Weighted Average of 334 Stocks 3.5%
Canada Minimum Threshold Dividend Yield 10th Percentile 1.1%
Canada Bottom 25% Dividend Yield 25th Percentile 2%
Canada Top 25% Dividend Yield 75th Percentile 5.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CNSX:MJAR Future Dividends Estimate Data
Date (Data in CA$) Dividend per Share (annual) Avg. No. Analysts
2020-12-31
2019-12-31
2019-09-22

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MJardin Group has not reported any payouts.
  • Unable to verify if MJardin Group's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MJardin Group's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MJardin Group has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MJardin Group's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MJardin Group afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MJardin Group has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of MJardin Group's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Adrian Montgomery
AGE 45
TENURE AS CEO 0.6 years
CEO Bio

Mr. Adrian Taylor Montgomery serve as Chief Executive Officer & Director at Enthusiast Gaming Holdings Inc. Mr. Montgomery is Chairman of MJardin Group, Inc. since February 19, 2019 and serves as its Chief Executive officer. He was Interim Chief Executive officer at MJardin Group, Inc since February 19, 2019. Mr. Montgomery serves as Chief Executive Officer and Director at J55 Capital Corp since June 27, 2018. He served as the Chief Executive Officer of Quantum Murray LP and was also the former CEO of QM Environmental, one of Canada’s largest contracting companies. Mr. Montgomery served as President at ClearStream Energy Services Inc. since December 17, 2014 until June 29, 2015. Mr. Montgomery served as the Chief Investment Officer of ClearStream Energy Services Inc. since its inception in 2005 until December 17, 2014. He is a key Member of the ClearStream Energy Services Inc. executive team that has reshaped ClearStream Energy Services Inc. over the past two years and was involved in the successful dispositions of clearstream’s non-core operations, consolidation of minority positions in clearstream’s core areas, securing new financing packages for clearstream, converting clearstream from an income trust to a corporation and engineering a total rebranding of the organization. He served as Vice President of Tuckamore Capital Management Inc. since January 2010 and was its President. He served as a Vice President of Newport Partners GP Inc since January 2010. He Headed business development at Rogers Media Inc., where he oversaw a number of business development initiatives in the fields of sports and entertainment. He has been a Director of NeuroBiopharm Inc. since June 20, 2014. He served as an Independent Director of Acasti Pharma Inc. since June 20, 2014 until February 29, 2016. He served as an Independent Director of Epsilon Energy Ltd. since July 15, 2013 May 20, 2019. He served as a Director of ClearStream Energy Services Inc since October 1, 2015 until June 21, 2017. He served as a Director of Neptune Technologies & Bioresources, Inc. from June 19, 2014 to July 215. He spearHeaded several landmark alliances with the National Football League, the International Olympic Committee, the FIFA World Cup, Live Nation Music and CBS Paramount. He was the President and Chief Information Officer of Tuckamore Capital Management Inc. from February 2012 to March 2016. A lawyer, Mr. Montgomery is active in the political process and has served as a Senior Adviser to politicians at all levels of government. In the past, he has been a sought after media personality and panelist on CBC and Global Television. He is a Member of the New York State Bar and the Young Presidents’ Organization. He is also involved in a number of charitable endeavours and sits on the Board of Special Olympics Canada and sits on the Board of the Toronto East General Hospital Foundation.

CEO Compensation
  • Insufficient data for Adrian to compare compensation growth.
  • Insufficient data for Adrian to establish whether their remuneration is reasonable compared to companies of similar size in Canada.
Management Team Tenure

Average tenure of the MJardin Group management team in years:

0.3
Average Tenure
  • The average tenure for the MJardin Group management team is less than 2 years, this suggests a new team.
Management Team

Adrian Montgomery

TITLE
Chairman & CEO
AGE
45
TENURE
0.6 yrs

Wendy Xue

TITLE
Interim Chief Financial Officer
TENURE
0.1 yrs

Pat Witcher

TITLE
Chief Operating Officer
TENURE
0.3 yrs

Max Nardulli

TITLE
Executive Vice President of International Corporate Development

Ben Franz

TITLE
Senior Vice President of Cultivation

Jeannette Harkin

TITLE
Senior VP & Chief of Staff

Eric Gattoni

TITLE
Senior Vice President of NA - West/Central

Christine Halef

TITLE
Senior Vice President of Atlantic Canada Operations
Board of Directors Tenure

Average tenure of the MJardin Group board of directors in years:

0.6
Average Tenure
  • The average tenure for the MJardin Group board of directors is less than 3 years, this suggests a new board.
Board of Directors

Adrian Montgomery

TITLE
Chairman & CEO
AGE
45
TENURE
0.6 yrs

Graham Marr

TITLE
Director
TENURE
0.8 yrs

Roman Kocur

TITLE
Director
TENURE
0.8 yrs

Lorne Sugarman

TITLE
Director
TENURE
0.6 yrs

James Lowe

TITLE
Director
AGE
38
TENURE
0.3 yrs

Glenn Hudson

TITLE
Director
TENURE
0.3 yrs
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by MJardin Group individual insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (CA$) Value (CA$)
18. Sep 19 Buy Graham Marr Individual 11. Sep 19 12. Sep 19 7,000 CA$1.08 CA$7,559
X
Management checks
We assess MJardin Group's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MJardin Group has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

What Does MJardin Group, Inc.'s (CNSX:MJAR) Balance Sheet Tell Us About It?

With this increase in debt, MJAR currently has CA$30m remaining in cash and short-term investments to keep the business going. … At the current liabilities level of CA$158m, it appears that the company arguably has a rather low level of current assets relative its obligations, with the current ratio last standing at 0.3x. … The current ratio is calculated by dividing current assets by current liabilities.

Simply Wall St -

How Financially Strong Is MJardin Group Inc (CNSX:MJAR)?

Investors are always looking for growth in small-cap stocks like MJardin Group Inc (CNSX:MJAR), with a market cap of CA$281m. … However, an important fact which most ignore is: how financially healthy is the business? … the current state of its operations and pathway to profitability.

Simply Wall St -

Company Info

Description

MJardin Group, Inc., through its subsidiaries, engages in the cultivation, processing, distribution, and retail of cannabis products in Canada. It also provides consulting, design, operational, and other management services, such as strategic capital and financing, project management services for cultivation, licensure support, facility design, systems implementation, equipment leasing, construction oversight, facility ramp-up, and day-to-day personnel management and oversight for licensed cannabis cultivators, processors, and dispensaries in the states of Colorado and Nevada in the United States and in the provinces of Ontario, Manitoba in Canada. The company owns, manages, or advises on a portfolio of 32 cannabis operations. MJardin Group, Inc. was founded in 2014 and is headquartered in Denver, Colorado.

Details
Name: MJardin Group, Inc.
MJAR
Exchange: CNSX
Founded: 2014
CA$48,572,660
67,462,028
Website: http://www.mjardin.com
Address: MJardin Group, Inc.
3461 Ringsby Court,
Suite 350,
Denver,
Colorado, 80216,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CNSX MJAR Common Shares Canadian National Stock Exchange CA CAD 15. Nov 2018
OTCPK MJAR.F Common Shares Pink Sheets LLC US USD 15. Nov 2018
Number of employees
Current staff
Staff numbers
0
MJardin Group employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/09/22 00:49
End of day share price update: 2019/09/20 00:00
Last estimates confirmation: 2019/08/30
Last earnings filing: 2019/08/29
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.